Skip to main content
rounds.

Evidence digest

Medical Retina: the evidence, summarized every weekday

Peer-reviewed papers in medical retina, summarized and ranked by evidence level. Top studies from PubMed and ClinicalTrials.gov. Updated every weekday at 06:00 CET. Built by physicians, for physicians.

Subscribe · €49 / year →See the methodology →

What rounds. covers in medical retina

  • AMD (anti-VEGF)
  • Diabetic retinopathy & DME
  • Retinal vein occlusion
  • Inherited retinal dystrophies
  • Central serous chorioretinopathy
  • Imaging (OCT/OCTA)

Landmark papers · medical retina

Hand-picked by the editorial team. These are the studies that shaped current practice in medical retina.

  1. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.

    JAMA · Chew E. et al. · Tuesday, January 1, 2013

  2. Ranibizumab for neovascular age-related macular degeneration.

    The New England journal of medicine · Rosenfeld P. et al. · Sunday, January 1, 2006

  3. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.

    The New England journal of medicine · Wells J. et al. · Thursday, January 1, 2015

  4. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials.

    Lancet · Heier J. et al. · Saturday, January 1, 2022

  5. L2 · prospective cohort

    Archway Randomized Phase 3 Trial of the Port Delivery System With Ranibizumab for Neovascular Age-Related Macular Degeneration.

    Ophthalmology · Holekamp N. et al. · Friday, January 1, 2021

How papers reach the medical retina brief

  1. Source. Every paper is fetched directly from PubMed and ClinicalTrials.gov. No paywalled aggregators. No editorial press releases.
  2. Grading. Each paper is assigned an evidence level from L1 (RCT or meta-analysis) to L5 (editorial). Bias risk is flagged separately. Both labels are visible on every card.
  3. Summarization. A 5-gate validator stack checks every summary for source faithfulness, numeric accuracy, drug-safety language, unsupported claims, and clinical-decision overreach. Anything that fails a gate is blocked, not silently weakened.
  4. Delivery. Ten papers. Twelve minutes. Every weekday at 06:00 CET. Subscribers can rate any paper as off-topic and it drops out of their feed.

The full pipeline, validators, and the founder's editorial overrides are documented on the methodology page.

Frequently asked

How do I keep up with new medical retina research?
rounds. reads the new medical retina literature from PubMed and ClinicalTrials.gov every weekday, grades each paper on the CEBM evidence hierarchy, and delivers the few that change practice as a twelve-minute morning brief. Every summary is checked claim by claim against the source paper.
What are the landmark medical retina trials?
The studies that shaped current medical retina practice are listed above under “Landmark papers”, each linked to a structured summary with its evidence level, effect size, and bias signals.
Is rounds. free?
The morning scan is free. Pro (€49 / year) unlocks the full ten-paper daily brief, the full read on every paper, and the 06:00 CET email, Monday to Friday.

Other subspecialties